Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.

Objective: In order to verify the safety and effectiveness of tirofiban combined with statins in the perioperative period of intracranial aneurysms, this study adopts systematic review and meta-analysis, so as to comprehensively understand the situation of intracranial aneurysms in the perioperative period, and tirofiban combined with statins was finally determined as an effective treatment drug.

Methods: This study used systematic retrospective analysis and selected 80 patients with intracranial aneurysms treated in our hospital from June 2021 to June 2022 as the research objects. Through conventional drugs and tirofiban combined with statins used in this study, the intracranial levels, the probability of aneurysm rupture, and postoperative complications of the two groups were observed and recorded.

ZEB2, interacting with MDM2, contributes to the dysfuntion of brain microvascular endothelial cells and brain injury after intracerebral hemorrhage.

ZEB2 has been shown to be upregulated in the brain tissues of rats with intracerebral hemorrhage (ICH), but its role in ICH-caused brain injury remains unclear. Here, an ICH rat model was established via intracerebral injection of autologous blood, and the lentivirus-mediated ZEB2 short hairpin RNA (sh-ZEB2) or negative control (scramble) were administered 0.5 hours after ICH.

Inhibition of EMMPRIN by microRNA-124 suppresses the growth, invasion and tumorigenicity of gliomas.

MicroRNAs (miR) are a group of non-coding, small RNAs, 18-20 nucleotides in length, that are frequently involved in the development of a variety of different types of cancer, including glioma, which is a type of severe tumor in the brain. Previous studies reported that miR-124 levels were downregulated in glioma specimens; however, the potential role of miR-124 in glioma currently remains unclear. The present study performed experiments, including dual-luciferase reporter assay (DLRA), MTT assay, transwell assay and flow cytometry, with the aim of elucidating the molecular mechanism of miR-124 in glioma.